Full-Time

Senior Analyst

Compliance

Updated on 9/3/2026

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

Compensation Overview

$84.5k - $162k/yr

+ Bonus

Waukegan, IL, USA

Hybrid

On-site required 3 days a week—Tuesday, Wednesday, and Thursday.

Bachelor's, Master's, JD

Category
Risk & Compliance (1)
Required Skills
Word/Pages/Docs
Data Analysis
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • B.A./B.S. degree required. CPA, Master's, JD, or equivalent work experience preferred.
  • Minimum of 5 years’ experience with, or exposure to, business functions such as compliance, legal, audit, finance, and regulatory affairs.
  • Builds strong relationships with colleagues, peers and cross functional partners outside of team to enable higher performance.
  • Leadership, organization, analytical, project management and team-building skills.
  • Can work independently with a high level of initiative. Learns fast, grasps the essence, and can change course quickly where required.
  • Highly organized, with excellent oral and written communication skills, technical skills, and Word, Excel, PowerPoint.
  • Attention to proofreading and editing skills, strong interpersonal and presentation skills.
  • Change agile – ability to be flexible and adjust strategy based on the evolving business.
  • Inquisitive and open minded – Ability to learn, understand and guide without bias in order to bring the best solution or alternatives that supports an efficient and effective Compliance program.
  • Enterprise mindset that proactively seeks to ideate and improve upon operational process by leveraging continued advancements in data, analytics, and AI -related tools, and as the business and our OEC teams evolve.
  • Strong ability to synthesize information and use expertise and judgment to evaluate what needs to be communicated based on objectives and audiences.
Responsibilities
  • Partners effectively with all levels of OEC to assess and identify support needs, provide support, advocate for escalation, and support continued momentum using available communication channels.
  • Creates, manages and executes project plans as well as develops related project materials (e.g., presentations, draft deliverables, implementation plans, etc.) necessary to execute on our OEC operational excellence framework and key strategic projects, revising, as appropriate, to meet changing needs.
  • Supports the global risk assessment process, including collecting, analyzing, and synthesizing, relevant qualitative and quantitative data points from cross functional stakeholders and leadership to inform the global OEC risk landscape; Summarizes and updates the risk assessment results, as necessary.
  • Collaborates across all OEC teams and other relevant functions (e.g., Internal Audit) to regularly identify and understand on-going, evolving, and emerging OEC-related risks. Supports ongoing training, communication, and engagement with the global OEC team to drive clarity, consistency, and rigor in the assessment process, and to drive engagement and ownership at all levels.
  • Supports the collection, oversight and integrity of master data/information that enables global risk assessment, including the governance of the OEC Risk Register, user profile, and other relevant data sources.
  • Identifies, delivers, and presents OEC-related risks and issues to management with proactive recommendations on addressing and mitigating the issues. Plans for and coordinates change management activities needed to embed project outcomes.
  • Supports innovation and drives efficiencies and consistency in our approach to OEC risk management, analytics and operational excellence.
  • Supports activities related to the operations and sustainability of the US Risk Governance model and future opportunities for global risk governance harmonization.
  • Leads the management of OEC resources (e.g., Prezentium, benchmarking), such as budget, PO, users, coordinating responses and reporting final deliverables, coordinating educational materials and project management resources and other tools.
  • Establishes teams around critical projects, motivates action at all levels, successfully encourages and leads teams to a specified goal, and uses compliance knowledge to translate and document meetings, and support project materials and outcomes.
  • Participates in and leads cross-functional OEC projects.
  • Assists with the preparation of department presentations and training materials.
  • Assists with remediation of compliance audits, works with the Compliance Directors and business partners to ensure timely completion, and functions as a liaison between OEC and Internal Audit.
  • Possesses solid working knowledge of AbbVie’s business, the current compliance environment, and the broader business impact.

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $16.99 billion, up 10.2%, and adjusted EPS reached $3.65.
  • FDA approved Decnupaz in May 2026, AbbVie’s first hematology ADC.
  • European approvals for Rinvoq in vitiligo and alopecia expand 2026 commercial reach.

What critics are saying

  • Imbruvica faced Medicare price cuts in 2026, accelerating oncology erosion and reimbursement pressure.
  • Oncology revenue fell 2.4% in Q2 2026 as Imbruvica dropped 29.4%.
  • Skyrizi-Rinvoq concentration leaves AbbVie vulnerable if one safety signal emerges.

What makes AbbVie unique

  • AbbVie’s Skyrizi and Rinvoq generated enough growth to replace Humira by 2025.
  • AbbVie now pairs immunology scale with oncology assets like Epkinly, Emrelis, and Decnupaz.
  • Apogee’s 2026 deal adds late-stage IL-13 and TSLP antibodies for eczema and asthma.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Sep 8th, 2026
AbbVie beats Pfizer as top dividend stock with 53-year payout streak and 203% growth

AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.

INSURASALES
Sep 5th, 2026
Manufacturers Life Insurance buys $655M stake in AbbVie as institutions boost pharma holdings

The Manufacturers Life Insurance Company acquired a $655.27 million stake in AbbVie Inc., according to its latest SEC Form 13F filing. Other institutional investors also increased their positions significantly during the same period. Norges Bank acquired a new $5.87 billion position, whilst Wellington Management Group boosted its holdings by 457.4%. AbbVie reported quarterly earnings per share of $3.65, exceeding forecasts, with revenue growth of 10.2% year over year. The company generated $16.99 billion in revenue last quarter, surpassing expectations. Equity analysts maintain a bullish outlook. Barclays, Wolfe Research, and BMO Capital Markets each set price targets of $300, with ratings of "overweight" or "outperform". The consensus rating is "Moderate Buy". Institutional investors currently hold 70.23% of AbbVie's shares, reflecting confidence in the biopharmaceutical company's strategy and performance.

PharmTech
Sep 4th, 2026
AAPS PharmSci 360: CMC strategies, part 1.

AAPS PharmSci 360: CMC strategies, part 1. In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discussed how CMC review practices are evolving and what that means for manufacturing strategy. PharmTech spoke with Alfred Rumondor, PhD, CMC due diligence for external assets at AbbVie, and Swita Singh, PhD, Senior Director and Strategic CMC Leader at Bristol Myers Squibb, to learn more about their upcoming panel discussion, Navigating CMC Strategy in the Current Landscape, at, which is being held from October 25-28 in New Orleans. In part 1 of this 3-part interview, Rumondor and Singh discussed how chemistry, manufacturing, and controls (CMC) review practices are evolving and what that means for manufacturing strategy. Singh identified the most consequential shift as a move from informal, reviewer-dependent flexibility to formal, risk-based flexibility applied consistently across the product life cycle. She pointed to Operation TrailBlazer and updated phase 1 CMC guidance as examples, stating they are reducing required manufacturing data pre-investigational new drug application (IND). Singh also pointed out that cell and gene therapy programs no longer need 3 independent process performance qualification batches and can flex specifications for small-batch production. AI-driven tools and emerging credibility frameworks are reinforcing this trend by helping generate cleaner data packages for faster, more consistent regulatory decisions. Singh cautioned, however, that companies must build "risk justification muscle" rather than simply accepting flexibility at face value. Reduced requirements should be treated as deferral, not elimination, of data obligations; organizations need clear plans for when deferred data will be generated and which milestones trigger it. She emphasized investing early in comparability infrastructure, leveraging platform and prior-knowledge pathways, and engaging proactively with regulators. Rumondor addressed the pressure to compress development timelines. He argued the real question isn't whether compression is safe, but how to do it properly by working smarter rather than skipping steps. He cited premature form selection without adequate screening as a common shortcut that later may bring costly bridging and comparability studies, increasing both timeline and program risk. Compressed timelines are achievable, but only when teams rigorously plan the full development path upfront, according to Rumondor. About the speakers. Alfred Rumondor, PhD, is Director, Development Sciences Licensing and Acquisitions, at AbbVie. Dr. Swita Singh holds a Ph.D. in Pharmaceutical Sciences and brings over fifteen years of distinguished expertise in Chemistry, Manufacturing, and Controls (CMC) development across biologics, antibody drug conjugates, and small molecules, with a proven record of driving strategic initiatives, optimizing complex business processes, and leading cross-functional teams to achieve regulatory and operational excellence. Recognized for delivering innovative, end-to-end CMC strategies that guide programs from early clinical development through successful commercialization, she has cultivated talent and shaped organizational culture throughout her career, while her commitment to stakeholder communication and cross-functional collaboration has consistently advanced program objectives across the industry. Having built her expertise at Pfizer and Eli Lilly and Company, Dr. Singh currently serves at Bristol Myers Squibb (BMS), where she continues to lead CMC strategy in support of transformative therapeutic development.

Yahoo Finance
Sep 3rd, 2026
AbbVie's etentamig shows 74% response rate in cancer trial, beating standard treatment by 28 percentage points

AbbVie's experimental cancer drug etentamig achieved a 74% overall response rate in a pivotal Phase 3 trial for relapsed or refractory multiple myeloma, significantly outperforming standard treatments at 45.7%. The study also met its progression-free-survival endpoint. The drug remains investigational pending regulatory review. AbbVie's oncology division reported $1.65 billion in second-quarter revenue, down 1.5%, representing roughly 9.7% of total sales. Venclexta grew 11.6%, whilst Imbruvica declined 29.4%. AbbVie shares traded at $260.445. The company requires new growth drivers as its existing oncology portfolio faces mixed performance. Detailed safety and durability data have not yet been disclosed.

Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.